Biodegradable ureteral stents, methods and uses thereof

Abstract

The present disclosure relates to biodegradable ureteral stents comprising an anti-cancer drug, and to a composition for use in medicine that may be used to ensure patency of a channel, namely a mammal ureter, for example, an obstructed ureter by a urinary stone, neoplasia or by a surgical procedure. The biodegradable ureteral stents (BUS) disclosed in the present disclosure unexpectedly allow a proper release of anti-cancer drugs, thus extending the duration of the treatment and increasing the efficacy of the treatment.

Description

technical field [0001] The present disclosure relates to biodegradable ureteral stents comprising anti-cancer drugs, and to compositions for use in medicaments useful for ensuring the patency of passageways, i.e., mammalian ureters, such as uroliths, neoplasia, or surgically obstructed ureters . Background technique [0002] Upper tract urothelial carcinoma (UTUC) accounts for 5-10% of urothelial carcinomas and is a disease that has not been studied as extensively as bladder cancer. To avoid the problems of conventional treatments, such as the need for frequent drug infusions due to poor drug retention, we developed a biodegradable ureteral stent (BUS) that was passed through supercritical fluid CO 2 (scCO 2 ) impregnated with the most commonly used anticancer drugs, namely paclitaxel, epirubicin, doxorubicin and gemcitabine. The release kinetics of anticancer therapeutics from drug-eluting stents were measured in artificial urine (AUS). In vitro release showed that for ...

AI Technical Summary

Problems solved by technology

These studies suggest that drug-eluting conventional double-J ureteral stents have limited efficacy in preclinical and clinical trials, possibly because of poor drug delivery to ureteral tissue (Krambeck et al., 2010; Lange et al., 2015; Mendez -Probst et al., 2012)

Images